↓ Skip to main content

Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

Overview of attention for article published in PharmacoEconomics - Open, August 2017
Altmetric Badge

Mentioned by

twitter
1 tweeter
facebook
1 Facebook page

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
20 Mendeley
Title
Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
Published in
PharmacoEconomics - Open, August 2017
DOI 10.1007/s41669-017-0048-x
Pubmed ID
Authors

Martina Garau, Grace Hampson, Nancy Devlin, Nicola Amedeo Mazzanti, Antonio Profico

Abstract

Healthcare decision makers need to make trade-offs between different elements of value of new treatments. Multicriteria decision analysis (MCDA) provides a framework that can help decision makers to understand stakeholders' preferences and be explicit about the trade-offs that are being made. The objective of this study was to use MCDA to obtain preferences and views on decision criteria across three stakeholder groups (patients, clinicians and payers) in Italy and to use these to assess the performance of obinutuzumab for rituximab-refractory indolent non-Hodgkin lymphoma (iNHL). We used EVIDEM V3.0, an MCDA framework, and collected participants' preferences via an online survey and structured meetings. Patients and clinicians expressed a preference for interventions targeting severe conditions. Payers expressed preference for treatments targeting areas with an unmet need, which are cheaper than the comparator, and with high-quality evidence. Obinutuzumab in combination with bendamustine, compared with bendamustine alone, received high positive scores for the criteria 'disease severity' and 'type of therapeutic benefit' by all three groups, and negative scores on the economic-related criteria, according to all stakeholder groups. MCDA can be used to elicit the views of different stakeholder groups and has the potential to structure and inform reimbursement decisions.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 1 5%
Unknown 19 95%

Demographic breakdown

Readers by professional status Count As %
Researcher 5 25%
Student > Bachelor 5 25%
Unspecified 3 15%
Student > Master 2 10%
Student > Ph. D. Student 2 10%
Other 3 15%
Readers by discipline Count As %
Unspecified 5 25%
Pharmacology, Toxicology and Pharmaceutical Science 3 15%
Agricultural and Biological Sciences 2 10%
Computer Science 2 10%
Business, Management and Accounting 2 10%
Other 6 30%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 August 2017.
All research outputs
#9,598,885
of 11,997,419 outputs
Outputs from PharmacoEconomics - Open
#1
of 1 outputs
Outputs of similar age
#194,852
of 266,125 outputs
Outputs of similar age from PharmacoEconomics - Open
#1
of 1 outputs
Altmetric has tracked 11,997,419 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1 research outputs from this source. They receive a mean Attention Score of 0.0. This one scored the same or higher as 0 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,125 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 15th percentile – i.e., 15% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them